Peppi Prasit, PhD
Peppi Prasit has more than 25 years of experience in pharmaceutical research and management. He is a founder of Inception Sciences, a small molecule drug discovery company. Prior to Inception Sciences, Peppi was co-founder and Chief Scientific Officer of Amira Pharmaceuticals, Inc., a pharmaceutical company focused on the discovery and early development of new small molecule drugs and chosen as one of the most promising biotech companies in 2010 by FierceBiotech. Amira successfully created five candidates entering clinical trials within five years from company inception. Included in these programs are AM103/AM803, oral inhibitors of 5-lipoxygenase activating protein (FLAP) partnered by GlaxoSmithKline, and AM152, a first-in-class LPA-1 receptor antagonist recently selected by Thomson Reuters as one of the five most promising drugs in Phase 1 clinical trials in the pharmaceutical industry (“Pharma Matters: The Ones To Watch”, Oct-Dec 2010).
Prior to Inception and Amira, Peppi held various positions with Merck including head of chemistry at the company's San Diego facility. While at Merck, Peppi was the lead scientist responsible for Vioxx, Arcoxia, Odanacatib and was involved in the optimization program that led to Singulair.
Peppi received his undergraduate degree from University College London in the UK, Ph.D. in chemistry from Victoria University of Wellington in New Zealand and served as a post-doctoral fellow at Princeton University in New Jersey.
